Skip to main
University-wide Navigation

The project aims to: 1) analyze gabapentin prescribing in Kentucky since July 1, 2017, when gabapentin became a Schedule V controlled substance; 2) evaluate the effect of Kentucky’s 2017 SB32, which amended KRS 218A.202 to require the Administrative Office of the Courts to forward drug conviction data to the Kentucky Cabinet for Health and Family Services for inclusion in KASPER (Kentucky All Schedule Prescription Electronic Reporting); and 3) develop continuing education for use of drug conviction data in clinical context.

CONTACT

  • Svetla Slavova, PhD, Principal Investigator
  • Trish Freeman, RPh, PhD, FAPhA, FNAP, Research Lead